EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab By Ogkologos - May 8, 2026 60 0 Facebook Twitter Google+ Pinterest WhatsApp It is a cancer medicine used to treat adult patients with multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR 3-in-1 Approach Helps Women in Rural Areas Get Cancer Screenings June 1, 2023 FDA Approves Sacituzumab Govitecan-hziy for HR-positive Advanced Breast Cancer February 15, 2023 Resilience Isn’t About Bouncing Back March 8, 2021 Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk... June 18, 2025 Load more HOT NEWS It Might Sound Trite But… Neoadjuvant Niraparib Demonstrates Promising Antitumour Activity and Safety in Patients with... FDA Approves Imlunestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... Study Examines Whether Blood Test Can Identify Early Cancers
